Convection-enhanced Diffusion: A Novel Tactics to Crack the BBB

Overview

Journal Curr Drug Deliv

Publisher Bentham Science Publishers

Specialty Pharmacology

Date 2024 Jan 26

PMID 38275045

Authors

Meenakshi Dhanawat

Garima

Kashish Wilson

Sumeet Gupta

Rishabh Chalotra

Nidhi Gupta

Affiliations

Soon will be listed here.

Abstract

Although the brain is very accessible to nutrition and oxygen, it can be difficult to deliver medications to malignant brain tumours. To get around some of these issues and enable the use of therapeutic pharmacological substances that wouldn't typically cross the blood-brain barrier (BBB), convection-enhanced delivery (CED) has been developed. It is a cutting-edge strategy that gets beyond the blood-brain barrier and enables targeted drug administration to treat different neurological conditions such as brain tumours, Parkinson's disease, and epilepsy. Utilizing pressure gradients to spread the medicine across the target area is the main idea behind this diffusion mechanism. Through one to several catheters positioned stereotactically directly within the tumour mass, around the tumour, or in the cavity created by the resection, drugs are given. This method can be used in a variety of drug classes, including traditional chemotherapeutics and cutting-edge investigational targeted medications by using positive-pressure techniques. The drug delivery volume must be optimized for an effective infusion while minimizing backflow, which causes side effects and lowers therapeutic efficacy. Therefore, this technique provides a promising approach for treating disorders of the central nervous system (CNS).

References

Brethour M, Nystrom K, Broughton S, Kiernan T, Perez A, Handler D . Controversies in acute stroke treatment. AACN Adv Crit Care. 2012; 23(2):158-72. DOI: 10.1097/NCI.0b013e31824fe1b6. View

Gabathuler R . Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2009; 37(1):48-57. DOI: 10.1016/j.nbd.2009.07.028. View

Pathan S, Iqbal Z, Zaidi S, Talegaonkar S, Vohra D, Jain G . CNS drug delivery systems: novel approaches. Recent Pat Drug Deliv Formul. 2009; 3(1):71-89. DOI: 10.2174/187221109787158355. View

DAmico R, Aghi M, Vogelbaum M, Bruce J . Convection-enhanced drug delivery for glioblastoma: a review. J Neurooncol. 2021; 151(3):415-427. PMC: 8034832. DOI: 10.1007/s11060-020-03408-9. View

Zlokovic B . The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008; 57(2):178-201. DOI: 10.1016/j.neuron.2008.01.003. View

Daneman R . The blood-brain barrier in health and disease. Ann Neurol. 2013; 72(5):648-72. DOI: 10.1002/ana.23648. View

Mulvihill J, Cunnane E, Ross A, Duskey J, Tosi G, Grabrucker A . Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers. Nanomedicine (Lond). 2020; 15(2):205-214. DOI: 10.2217/nnm-2019-0367. View

Dhanawat M, Gupta S, Mehta D, Das R . Design, Synthesis and Enhanced BBB Penetration Studies of L-serine-Tethered Nipecotic Acid-Prodrug. Drug Res (Stuttg). 2020; 71(2):94-103. DOI: 10.1055/a-1290-0119. View

Patel M, Patel B . Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain. CNS Drugs. 2017; 31(2):109-133. DOI: 10.1007/s40263-016-0405-9. View

10.

Daneman R, Prat A . The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015; 7(1):a020412. PMC: 4292164. DOI: 10.1101/cshperspect.a020412. View

11.

Pardridge W . Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS. 2011; 8(1):7. PMC: 3042981. DOI: 10.1186/2045-8118-8-7. View

12.

Leece R, Xu J, Ostrom Q, Chen Y, Kruchko C, Barnholtz-Sloan J . Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. Neuro Oncol. 2017; 19(11):1553-1564. PMC: 5737839. DOI: 10.1093/neuonc/nox091. View

13.

Sampson J, Maus M, June C . Immunotherapy for Brain Tumors. J Clin Oncol. 2017; 35(21):2450-2456. DOI: 10.1200/JCO.2017.72.8089. View

14.

Burns M, Weiss W . Targeted therapy of brain tumors utilizing neural stem and progenitor cells. Front Biosci. 2002; 8:e228-34. DOI: 10.2741/953. View

15.

Bobo R, Laske D, Akbasak A, Morrison P, Dedrick R, Oldfield E . Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994; 91(6):2076-80. PMC: 43312. DOI: 10.1073/pnas.91.6.2076. View

16.

Morrison P, Laske D, Bobo H, Oldfield E, Dedrick R . High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994; 266(1 Pt 2):R292-305. DOI: 10.1152/ajpregu.1994.266.1.R292. View

17.

Lonser R, Walbridge S, Garmestani K, Butman J, Walters H, Vortmeyer A . Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg. 2002; 97(4):905-13. DOI: 10.3171/jns.2002.97.4.0905. View

18.

Nguyen T, Pannu Y, Sung C, Dedrick R, Walbridge S, Brechbiel M . Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg. 2003; 98(3):584-90. DOI: 10.3171/jns.2003.98.3.0584. View

19.

Barua N, Gill S, Love S . Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations. Brain Pathol. 2013; 24(2):117-27. PMC: 8028869. DOI: 10.1111/bpa.12082. View

20.

Corem-Salkmon E, Ram Z, Daniels D, Perlstein B, Last D, Salomon S . Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles. Int J Nanomedicine. 2011; 6:1595-602. PMC: 3160945. DOI: 10.2147/IJN.S23025. View